Adults:
900 mgQID for 7 days
1g QID for 2 weeks; then suppressive therapy of 500 mg 4 times/day
Children 3 months to 12 years: 55 mg/kg/day divided every 6 hours;
suppressive therapy is 30 mg/kg/day divided every 6 hours
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Nalidixic Acid | Globe | 500mg | 56s/500s | Caps | Per Cap | KES 384/3132 | |
| Nalidixic Acid | Regal | 500mg | 100s | tab | perb tab | KES 904 | |
| Nalidixic Acid | LAE | 500mg | 100s | ta | per tab | KES 450 | |
| Nalidixic Acid | flamingo | 500mg | 100 | tabs | per tab | KES 460 | |
| Nalidixic Acid | PMC | 500mg | 100 | tabs | per tab | KES 490 | |
| Nalidixic Acid | Cosmos | 500mg | 100s | tabs | per tab | KES 1200 | |
| Dawaseptic | DAWA Pharmaceuticals Ltd | dawa Pharmaceuticals Ltd. | 500mg | 100s | tabs | KES 600 | |
| Gramofil | Beta | 500mg | 100s | Tablet | per tablet | KES 678.00 |
| Mode Of Action | interferes with bacterial DNA synthesis by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV. |
|---|---|
| Drug Indication | UTI resistant to other antibiotics |
| Precautions | A relatively high incidence of phototoxic reactions has been seen in patients taking Nalidixic Acid . Patients should be advised to avoid exposure to sunlight during, and for a few days after, Nalidixic Acid therapy, and to stop the drug immediately if phototoxicity occurs. Risk of phototoxicity may be reduced by taking Nalidixic Acid in the evening. |
| Contra-Indications | History of tendon disorders related to quinolone use, documented hypersensitivity. |
| Side Effects | High incidence of photosensitivity,convulsions, |
| Dosage | Usual dose is 400 mg once daily for 10 to 14 days. A dose of 400 mg once daily for 3 days is suitable in women with acute uncomplicated cystitis.For surgical infection prophylaxis a single 400 mg dose is given 1 to 6 hours before the procedure. |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Fluoroquinolones |